Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LNCB74

Antibody-drug conjugate · Cytotoxic, directed at B7-H4 (VTCN1) · developed by NextCure

Phase 1 Most advanced trial
NXTC Developer

What is LNCB74?

LNCB74 is an antibody-drug conjugate that binds B7-H4, a checkpoint ligand expressed on tumor cells and tumor-associated macrophages. After internalization, the linked MMAE payload is released by beta-glucuronidase and disrupts microtubule polymerization. It is being studied in advanced solid tumors, including ovarian, breast, endometrial, biliary tract and non-small cell lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
B7-H4 (VTCN1), tubulin (secondary target)
Mechanism
Cytotoxic, directed at B7-H4 (VTCN1)
Pathways
G2/M cell cycle arrest, apoptosis, bystander killing of neighboring tumor cells, immune-mediated cell death
Therapy area
Oncology
Developer
NextCure, Inc. (NXTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced or Metastatic Solid TumorsBiliary Tract CancerBreast CancerEndometrial CancerNon-Small Cell Lung CancerOvarian Cancer

Other drugs acting on VTCN1

More from NextCure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.

Follow NXTC, the company behind LNCB74

See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NXTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.